Dr Mesa presents, at a press conference at ASCO 2015, findings from the PERSIST-1 study of patients with myelofibrosis that suggest that pacritinib is significantly more effective than best available therapy (BAT), which includes a range of off-label treatments.
Read the news article and watch the interview for more.